PuSH - Publication Server of Helmholtz Zentrum München

Kraus, K.M.* ; Fischer, J.C.* ; Borm, K.J.* ; Vogel, M.M.E.* ; Pigorsch, S.U.* ; Devečka, M.* ; Combs, S.E.

Evaluation of practical experiences of German speaking radiation oncologists in combining radiation therapy with checkpoint blockade.

Sci. Rep. 11:7624 (2021)
Publ. Version/Full Text Research data DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
The results of this survey reveal current clinical practice in the handling of combined radioimmunotherapy with Immune Checkpoint Inhibitors (RT + ICI). We aim to provide a basis to open a discussion for clinical application of RT + ICI by analyzation of experts’ assessment. We conducted a survey with 24 items with a focus on side effects of RT + ICI, common practice of scheduling and handling of adverse events. After pilot testing by radiation oncology experts the link to the online survey was sent to all members of the German Society of Radiation Oncology (DEGRO). In total, 51 radiation oncologists completed the questionnaire. Pulmonary toxicity under RT + ICI with ICIs was reported most frequently. Consensus was observed for bone and soft tissue RT of the limbs in favor for no interruption of ICIs. For cranial RT half of the participants do not suspend ICIs during normofractionated radiotherapy (nfRT) or stereotactic hypofractionated RT (SRT). More participants pause ICIs for central than for peripheral thoracic region. Maintenance therapy with ICIs is mostly not interrupted prior to RT. For management of RT associated pneumonitis under durvalumab the majority of 86.3% suggest corticosteroid therapy and 76.5% would postpone the next cycle of ICI therapy. The here obtained assessment and experiences by radiation oncologists reveal a large variability in practical handling of combined RT + ICI. Until scientific evidence is available a discussion for current clinical application of RT + ICI should be triggered. Interdisciplinary consensus guidelines with practical recommendations are required.
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
4.379
1.377
2
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Stereotactic Body Radiotherapy; Cell Lung-cancer; Clinical-outcomes; Targeted Therapy; Immunotherapy; Safety; Radiosurgery; Ipilimumab; Melanoma; Pembrolizumab
Language english
Publication Year 2021
HGF-reported in Year 2021
ISSN (print) / ISBN 2045-2322
e-ISSN 2045-2322
Quellenangaben Volume: 11, Issue: 1, Pages: , Article Number: 7624 Supplement: ,
Publisher Nature Publishing Group
Publishing Place London
Reviewing status Peer reviewed
POF-Topic(s) 30203 - Molecular Targets and Therapies
Research field(s) Radiation Sciences
PSP Element(s) G-501300-001
Grants Else Kroner-Forschungskolleg (Else Kroner-Fresenius-Stiftung) of the Technical University of Munich (TUM)
Scopus ID 85103677295
PubMed ID 33828117
Erfassungsdatum 2021-04-16